A5077521993- Dementia and Cognitive Impairment Research
- Virus-based gene therapy research
- Alzheimer's disease research and treatments
- Retinal Development and Disorders
- RNA regulation and disease
- Retinal Diseases and Treatments
- Ocular Disorders and Treatments
- Retinal and Optic Conditions
- Tryptophan and brain disorders
- Neurological Disease Mechanisms and Treatments
- Cognitive Functions and Memory
- Cholinesterase and Neurodegenerative Diseases
- COVID-19 Clinical Research Studies
- Memory Processes and Influences
- Aging and Gerontology Research
- Long-Term Effects of COVID-19
- RNA Interference and Gene Delivery
- Geriatric Care and Nursing Homes
- Health disparities and outcomes
- COVID-19 and Mental Health
Yale University
2022-2023
St. George's University
2015
Brigham and Women's Hospital
2013-2014
Harvard University
2013-2014
Massachusetts General Hospital
2014
UMass Memorial Medical Center
2011
University of Massachusetts Chan Medical School
2010-2011
Neuropsychologists are developing more challenging and specific tests to detect early subtle changes in cognition related preclinical Alzheimer's disease (AD). The 16-item Face–Name Associative Memory Exam (FNAME-16) is a paired associative memory test able associated with biomarker evidence of AD. However, as individuals progress along the AD trajectory, measures that sensitive at stage may become too by Mild Cognitive Impairment (MCI). Our goal was develop modified version face–name...
Background: Impairment in instrumental activities of daily living (IADL) begins as individuals with amnestic mild cognitive impairment (MCI) transition to Alzheimer's disease (AD) dementia. IADL AD dementia has been associated infe
Introduction: Alzheimer's disease (AD) begins to develop decades prior its clinical manifestation (Sperling et al., 2011), and while it is the most common form of dementia, as yet there no cure. Two researched pathological features contributing development are extracellular amyloid plaques composed amyloid-beta proteins (Aβ) neurofibrillary tangles tau proteins. Another feature AD progression early neuronal excitability/hyperactivity silencing/hypoactivity (Palop Mucke, 2010), with...
Impairment in activities of daily living (ADL) is a major burden for Alzheimer's disease (AD) dementia patients and caregivers. Multiple subjective scales few performance-based instruments have been validated proven to be reliable measuring instrumental ADL AD but less so amnestic mild cognitive impairment (MCI). Our objective was validate new instrument early AD, which taps the high level tasks that challenge seniors life. One hundred twenty-nine subjects (91 clinically normal elderly (CN),...
Impairment in instrumental activities of daily living (IADL) begins as individuals with amnestic mild cognitive impairment (MCI) transition to Alzheimer's disease (AD) dementia. IADL AD dementia has been associated inferior parietal, temporal, and superior occipital hypometabolism using 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET). The objective this study was investigate the relationship between regional FDG metabolism cross-sectionally longitudinally clinically normal...